Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.7606
-0.0432-5.37%
Post-market: 0.78010.0195+2.56%17:52 EDT
Volume:1.12M
Turnover:878.01K
Market Cap:23.81M
PE:-0.24
High:0.8330
Open:0.8000
Low:0.7510
Close:0.8038
52wk High:5.25
52wk Low:0.7365
Shares:31.31M
Float Shares:26.89M
Volume Ratio:0.80
T/O Rate:4.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.21
PE(LYR):-0.13

Loading ...

Sep 16, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 16, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 09, 2024

Major Issues Report

Form 8-K - Current report
Sep 05, 2024

Major Issues Report

Form 8-K - Current report
Aug 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2024

Major Issues Report

Form 8-K - Current report
Jul 17, 2024

Major Issues Report

Form 8-K - Current report
Jul 16, 2024

Major Issues Report

Form 8-K - Current report
Jun 25, 2024

Major Issues Report

Form 8-K - Current report
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 12, 2024

Major Issues Report

Form 8-K - Current report
Jun 06, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Jun 05, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2024

Major Issues Report

Form 8-K - Current report